{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:22:15Z","timestamp":1787775735918,"version":"build-2784847793"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>In the current study, we aimed to evaluate the characteristics of individuals with autoimmune inflammatory myopathies (AIMs) in Isfahan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and Methods:<\/jats:title>\n                    <jats:p>In this retrospective, observational study, the clinical, histopathological, immunohistochemical staining, electromyography, and autoantibody profile of the patients with AIM in subgroups of dermatomyositis (DM), necrotizing autoimmune myopathy (NAM), polymyositis (PM), and antisynthetase syndrome (AS) were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Seventy-seven patients with AIMs including 38 (49.3%), 21 (27.3%), 14 (18.2%), and 4 (5.2%) with NAM, DM, PM, and antisynthetase diagnoses were enrolled, respectively. Proximal weakness (94.80%), myalgia (32.46%), skin rash (25.97%), and dysphagia (25.97%) were the most common presentations, among which skin rash was statistically more frequent in DM (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value = 0.001). Fiber necrosis (100%), CD68 (92.1%), and C5-b9 (60.5%) positivity, irritable myopathy (78.9%), and anti-Ro-52 (7.1%) positivity were the most common findings in NAM. Perivascular infiltration (71.4%), fiber degeneration (66.7%) and necrosis (52.4%), CD68 (100%), CD20 (71.4%), and CD8 (71.4%), both irritable (57.1%) and non-irritable (38.1%) myopathy, anti-Mi-2 (19%), anti-NXP-2 (19%), and anti-MDA-5 (14.3%) autoantibodies were the detected characteristics of DM patients. PM individuals were characterized with endomysial infiltration (92.9%), fiber necrosis (71.4%) and perivascular infiltration (64.3%), CD68 (100%), CD20 (100%) and CD8 (92.9%) positivity, both irritable (57.1%) and non-irritable (42.9%) myopathy and anti-Mi-2 (14.3%), and anti-ANA (14.3%) antibodies. Fiber necrosis (100%) and degeneration (75%), CD68 (75%), CD8 (75%), and C5-b9 (75%), irritable myopathy (50%), and anti-Jo-1 antibody (100%) positivity were the diagnostic tools for AS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>According to the outcomes of the current study, the clinical, histopathological, and autoantibody profiles of the patients with AIM are variably different with remarkable overlaps. Therefore, thorough assessments are required to make the final diagnosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/abr.abr_304_23","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T09:00:07Z","timestamp":1772182807000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Findings, Antibody Panel and Pathology of Patients with Inflammatory Myopathies in Isfahan Province, Iran"],"prefix":"10.4103","volume":"15","author":[{"given":"Behnaz","family":"Ansari","sequence":"first","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keivan","family":"Basiri","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"},{"name":"Department of Neurology, Medical School, Isfahan Neuroscience Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faeze","family":"Soroush","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2]]},"reference":[{"key":"R1-20260302","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/20009666.2020.1793478","article-title":"Utilization of myositis antibody-specific panel for diagnosis, treatment, and evaluation of disease progression","volume":"10","author":"Stark","year":"2020","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"R2-20260302","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/rheumatology\/keu289","article-title":"Incidence and prevalence of inflammatory myopathies: A systematic review","volume":"54","author":"Meyer","year":"2015","journal-title":"Rheumatology"},{"key":"R3-20260302","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1590\/0004-282x-anp-2022-s131","article-title":"Inflammatory myopathies: An update for neurologists","volume":"80","author":"Silva","year":"2022","journal-title":"Arq Neuropsiquiatr"},{"key":"R4-20260302","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JND-180308","article-title":"Current classification and management of inflammatory myopathies","volume":"5","author":"Schmidt","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"R5-20260302","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-020-00947-y","article-title":"Diagnostic value of muscle ultrasound for myopathies and myositis","volume":"22","author":"Albayda","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"R6-20260302","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/rheumatology\/keab553","article-title":"Limb girdle muscular dystrophy R12 (LGMD 2L, anoctaminopathy) mimicking idiopathic inflammatory myopathy: Key points to prevent misdiagnosis","volume":"61","author":"Marago","year":"2022","journal-title":"Rheumatology"},{"key":"R7-20260302","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMra1402225","article-title":"Inflammatory muscle diseases","volume":"372","author":"Dalakas","year":"2015","journal-title":"N Engl J Med"},{"key":"R8-20260302","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/rheumatology\/kew503","article-title":"Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: A nationwide population-based study","volume":"56","author":"Svensson","year":"2017","journal-title":"Rheumatology"},{"key":"R9-20260302","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/mus.23302","article-title":"Epidemiology of adult idiopathic inflammatory myopathies in a US managed care plan","volume":"45","author":"Furst","year":"2012","journal-title":"Muscle Nerve"},{"key":"R10-20260302","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R11-20260302","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11926-021-01017-7","article-title":"Updates on the immunopathology in idiopathic inflammatory myopathies","volume":"23","author":"Uruha","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"R12-20260302","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11926-018-0732-6","article-title":"Immune-mediated necrotizing myopathy","volume":"20","author":"Pinal-Fernandez","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"R13-20260302","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","article-title":"Immune-mediated necrotizing myopathy: Clinical features and pathogenesis","volume":"16","author":"Allenbach","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"R14-20260302","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11926-010-0100-7","article-title":"Cutaneous manifestations of dermatomyositis and their management","volume":"12","author":"Callen","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"R16-20260302","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41598-017-00240-6","article-title":"Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts","volume":"7","author":"Ge","year":"2017","journal-title":"Sci Rep"},{"key":"R17-20260302","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s10067-024-06873-z","article-title":"Clinical and immunological characteristics and prognosis of patients with autoantibody negative dermatomyositis: A case control study","volume":"43","author":"Xing","year":"2024","journal-title":"Clin Rheumatol"},{"key":"R18-20260302","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/imj.15358","article-title":"Idiopathic inflammatory myopathies: A review","volume":"51","author":"Ashton","year":"2021","journal-title":"Int Med J"},{"key":"R19-20260302","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.semarthrit.2019.04.002","article-title":"Immune-mediated necrotising myopathy: A critical review of current concepts","volume":"49","author":"Day","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"R20-20260302","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/WCO.0000000000000740","article-title":"Classification of idiopathic inflammatory myopathies: Pathology perspectives","volume":"32","author":"Tanboon","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"R21-20260302","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.nmd.2014.12.001","article-title":"205th ENMC International Workshop: Pathology diagnosis of idiopathic inflammatory myopathies part II 28\u201330 March 2014, Naarden, The Netherlands","volume":"25","author":"De Bleecker","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"R22-20260302","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/jnen\/nlaa023","article-title":"Gasdermine E-dependent mitochondrial pyroptotic pathway in dermatomyositis: A possible mechanism of perifascicular atrophy","volume":"79","author":"Liu","year":"2020","journal-title":"J Neuropathol Exp Neurol"},{"key":"R23-20260302","first-page":"408","article-title":"Comparison of muscle biopsy features with myositis autoantibodies in inflammatory myopathies: A pilot experience","volume":"26","author":"Gudipati","year":"2023","journal-title":"Ann Indian Acad Neurol"},{"key":"R24-20260302","doi-asserted-by":"crossref","first-page":"199","DOI":"10.55563\/clinexprheumatol\/vskjxi","article-title":"Idiopathic inflammatory myopathies: One year in review 2021","volume":"40","author":"Cardelli","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"R25-20260302","first-page":"199","article-title":"Idiopathic inflammatory myopathies: One year in review 2022","volume":"41","author":"Dourado","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"R26-20260302","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1212\/WNL.0000000000002291","article-title":"Hepatitis C virus infection in inclusion body myositis: A case-control study","volume":"86","author":"Uruha","year":"2016","journal-title":"Neurology"},{"key":"R27-20260302","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","article-title":"Dermatomyositis: Clinical features and pathogenesis","volume":"82","author":"DeWane","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R28-20260302","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1749-6632.2009.05119.x","article-title":"Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis","volume":"1184","author":"Mammen","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"R29-20260302","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J Autoimmun"},{"key":"R30-20260302","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.nmd.2019.10.005","article-title":"239th ENMC international workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14\u201316 December 2018","volume":"30","author":"Mammen","year":"2020","journal-title":"Neuromuscul Disord"}],"container-title":["Advanced Biomedical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/abr.abr_304_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:40:53Z","timestamp":1787773253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/abr.abr_304_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/abr.abr_304_23","relation":{},"ISSN":["2277-9175"],"issn-type":[{"value":"2277-9175","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2023-08-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}